FN1 and neoplasm: Thus, targeting glioma cells by co-delivering integrin αvβ3 inhibitor SB273005 with the chemotherapeutic TMZ might be advantageous to suppress αvβ3-positive tumor cells induced by collagen/FN as well as the integrin αvβ3 negative tumor cells with a low proliferative rate.